SCHEMBL6628766

SCHEMBL6628766

O=c1ccn(-c2nc(-c3ccc(Cl)cc3)cs2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.58
MAPT P10636 7/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 2/20 0.53
POLB P06746 1/20 0.53
GAA P10253 1/20 0.53
ALOX12 P18054 1/20 0.53
HTT P42858 1/20 0.53
BLM P54132 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
RAB9A P51151 6/20 0.52
NPC1 O15118 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
MAPK1 P28482 2/20 0.52
SIRT5 Q9NXA8 3/20 0.48
LMNA P02545 3/20 0.47
TSHR P16473 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8799905 0.86 AR (0.62) ARMAPTMEN1KMT2AKDM4E
SCHEMBL14678567 0.71 AR (0.62) ARMAPTMEN1KMT2AKDM4E
SCHEMBL4083245 0.71 NPC1 (0.60) ARMAPTMEN1KMT2AKDM4E
SCHEMBL15269219 0.71 MAPT (0.54) ARMAPTMEN1KMT2AKDM4E
SCHEMBL8798821 0.70 AR (0.61) ARMAPTMEN1KMT2AKDM4E
SCHEMBL14755578 0.69 CYP19A1 (0.61) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL4077609 0.69 MAPT (0.52) ARMAPTMEN1KMT2AKDM4E
SCHEMBL487145 0.69 MAPT (0.74) ARMAPTMEN1KMT2AKDM4E
SCHEMBL29157423 0.69 SMN1; SMN2 (0.70) ARMAPTMEN1KMT2AHTT
SCHEMBL430121 0.68 LTA4H (0.83) ARMAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-12-30 US disclosed
EP-1432706-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027085-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors CYP17A1, CYP21A2, HSD17B1 AR 383/4885MAPT 1946/4885MEN1 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.